217 related articles for article (PubMed ID: 35216782)
1. The Turkish experience of COVID-19 infection in people with NMOSD and MOGAD: A milder course?
Sen S; Tuncer A; Ozakbas S; Uzunkopru C; Baba C; Demir S; Beckmann Y; Gumus H; Arslan G; Kilic AK; Altintas A; Yuceyar N; Turan OF; Tutuncu M; Terzi M; Acar P; Bunul SD; Balci BP; Bir LS; Koseoglu M; Mungan S; Gunduz T; Dogan IG; Kotan D; Uygunoglu U; Ekmekci O; Demirkiran M; Kamisli O; Kabay SC; Tamam Y; Omerhoca S; Sevim S; Guler S; Kurtuncu M; Efendi H; Karabudak R; Siva A
Mult Scler Relat Disord; 2022 Feb; 58():103399. PubMed ID: 35216782
[TBL] [Abstract][Full Text] [Related]
2. COVID-19 in Patients With Neuromyelitis Optica Spectrum Disorders and Myelin Oligodendrocyte Glycoprotein Antibody Disease in North America: From the COViMS Registry.
Newsome SD; Cross AH; Fox RJ; Halper J; Kanellis P; Bebo B; Li D; Cutter GR; Rammohan KW; Salter A
Neurol Neuroimmunol Neuroinflamm; 2021 Sep; 8(5):. PubMed ID: 34429342
[TBL] [Abstract][Full Text] [Related]
3. COVID-19 infection after two doses of SARS-CoV-2 mRNA vaccine in multiple sclerosis, AQP4-antibody NMOSD and MOGAD.
Yeo T; Quek AML; Yong KP; Tye JSN; Ratnagopal P; Soon DTL; Tan K
Mult Scler Relat Disord; 2022 Sep; 65():104003. PubMed ID: 35803084
[TBL] [Abstract][Full Text] [Related]
4. Neuromyelitis optica spectrum disorders and myelin oligodendrocyte glycoprotein antibody-associated disease: current topics.
Fujihara K; Cook LJ
Curr Opin Neurol; 2020 Jun; 33(3):300-308. PubMed ID: 32374571
[TBL] [Abstract][Full Text] [Related]
5. Effects of the COVID-19 Pandemic on Patients With NMO Spectrum Disorders and MOG-Antibody-Associated Diseases: COPANMO(G)-Study.
Hümmert MW; Bütow F; Tkachenko D; Ayzenberg I; Pakeerathan T; Hellwig K; Klotz L; Häußler V; Stellmann JP; Warnke C; Goereci Y; Etgen T; Luessi F; Bronzlik P; Gingele S; Lauenstein AS; Kleiter I; Rommer PS; Paul F; Bellmann-Strobl J; Duchow A; Then Bergh F; Pul R; Walter A; Pellkofer H; Kümpfel T; Pompsch M; Kraemer M; Albrecht P; Aktas O; Ringelstein M; Senel M; Giglhuber K; Berthele A; Jarius S; Wildemann B; Trebst C;
Neurol Neuroimmunol Neuroinflamm; 2023 Mar; 10(2):. PubMed ID: 36693760
[TBL] [Abstract][Full Text] [Related]
6. Clinicoradiological comparative study of Aquaporin-4-IgG seropositive neuromyelitis optica spectrum disorder (NMOSD) and MOG antibody associated disease (MOGAD): A prospective observational study and review of literature.
Nagireddy RBR; Kumar A; Singh VK; Prasad R; Pathak A; Chaurasia RN; Mishra VN; Joshi D
J Neuroimmunol; 2021 Dec; 361():577742. PubMed ID: 34655992
[TBL] [Abstract][Full Text] [Related]
7. Risk of disease relapse following COVID-19 vaccination in patients with AQP4-IgG-positive NMOSD and MOGAD.
Dinoto A; Sechi E; Ferrari S; Gajofatto A; Orlandi R; Solla P; Maccabeo A; Maniscalco GT; Andreone V; Sartori A; Manganotti P; Rasia S; Capra R; Mancinelli CR; Mariotto S
Mult Scler Relat Disord; 2022 Feb; 58():103424. PubMed ID: 35216793
[TBL] [Abstract][Full Text] [Related]
8. Anti-MOG associated disorder-Clinical and radiological characteristics compared to AQP4-IgG+ NMOSD-A single-center experience.
Rempe T; Tarhan B; Rodriguez E; Viswanathan VT; Gyang TV; Carlson A; Tuna IS; Rees J
Mult Scler Relat Disord; 2021 Feb; 48():102718. PubMed ID: 33388560
[TBL] [Abstract][Full Text] [Related]
9. Disability outcomes in NMOSD and MOGAD patients: data from a nationwide registry in Argentina.
Rojas JI; Pappolla A; Patrucco L; Cristiano E; Miguez J; Liwacki S; Tkachuk V; Balbuena ME; Vrech C; Deri N; Correale J; Marrodan M; Ysrraelit MC; Fiol M; Leguizamon F; Luetic G; Menichini ML; Lopez PA; Pettinicchi JP; Criniti J; Caride A; Tavolini D; Mainella C; Zanga G; Burgos M; Hryb J; Barboza A; Lazaro L; Alonso R; Silva B; Fernández Liguori N; Nadur D; Chercoff A; Martinez A; Steinberg J; Garcea O; Carrá A; Alonso Serena M; Carnero Contentti E
Neurol Sci; 2023 Jan; 44(1):281-286. PubMed ID: 36166174
[TBL] [Abstract][Full Text] [Related]
10. Clinical and immunological differences between MOG associated disease and anti AQP4 antibody-positive neuromyelitis optica spectrum disorders: Blood-brain barrier breakdown and peripheral plasmablasts.
Tanaka S; Hashimoto B; Izaki S; Oji S; Fukaura H; Nomura K
Mult Scler Relat Disord; 2020 Jun; 41():102005. PubMed ID: 32114369
[TBL] [Abstract][Full Text] [Related]
11. Frequency of New Silent MRI Lesions in Myelin Oligodendrocyte Glycoprotein Antibody Disease and Aquaporin-4 Antibody Neuromyelitis Optica Spectrum Disorder.
Camera V; Holm-Mercer L; Ali AAH; Messina S; Horvat T; Kuker W; Leite MI; Palace J
JAMA Netw Open; 2021 Dec; 4(12):e2137833. PubMed ID: 34878547
[TBL] [Abstract][Full Text] [Related]
12. Serum Neurofilament Light and GFAP Are Associated With Disease Severity in Inflammatory Disorders With Aquaporin-4 or Myelin Oligodendrocyte Glycoprotein Antibodies.
Chang X; Huang W; Wang L; ZhangBao J; Zhou L; Lu C; Wang M; Yu J; Li H; Li Y; Zhao C; Lu J; Quan C
Front Immunol; 2021; 12():647618. PubMed ID: 33796113
[No Abstract] [Full Text] [Related]
13. Evaluation of the safety profile of COVID-19 vaccines in patients with MS, NMOSD, and MOGAD.
Kim S; Seok HY
Neurol Sci; 2023 Jun; 44(6):1841-1848. PubMed ID: 36781562
[TBL] [Abstract][Full Text] [Related]
14. Chiasmatic lesions on conventional magnetic resonance imaging during the first event of optic neuritis in patients with neuromyelitis optica spectrum disorder and myelin oligodendrocyte glycoprotein-associated disease in a Latin American cohort.
Carnero Contentti E; López PA; Criniti J; Pettinicchi JP; Cristiano E; Patrucco L; Bribiesca Contreras E; Gómez-Figueroa E; Flores-Rivera J; Correa-Díaz EP; Toral Granda AM; Ortiz Yepez MA; Gualotuña Pachacama WA; Piedra Andrade JS; Galleguillos L; Tkachuk V; Nadur D; Daccach Marques V; Soto de Castillo I; Casas M; Cohen L; Alonso R; Caride A; Lana-Peixoto M; Rojas JI
Eur J Neurol; 2022 Mar; 29(3):802-809. PubMed ID: 34799965
[TBL] [Abstract][Full Text] [Related]
15. Is there a link between neuropathic pain and constipation in NMOSD and MOGAD? Results from an online patient survey and possible clinical implications.
Lotan I; Romanow G; Levy M; Kister I
Mult Scler Relat Disord; 2022 Jul; 63():103825. PubMed ID: 35537276
[TBL] [Abstract][Full Text] [Related]
16. Outcomes of coronavirus disease 2019 in patients with neuromyelitis optica and associated disorders.
Louapre C; Maillart E; Papeix C; Zeidan S; Biotti D; Lepine Z; Wahab A; Zedet M; Labauge P; Tilikete C; Pique J; Tourbah A; Mathey G; Dimitri Boulos D; Branger P; Kremer LD; Marignier R; Collongues N; De Seze J
Eur J Neurol; 2021 Oct; 28(10):3461-3466. PubMed ID: 33103295
[TBL] [Abstract][Full Text] [Related]
17. Relapse activity in the chronic phase of anti-myelin-oligodendrocyte glycoprotein antibody-associated disease.
Akaishi T; Misu T; Fujihara K; Takahashi T; Takai Y; Nishiyama S; Kaneko K; Fujimori J; Ishii T; Aoki M; Nakashima I
J Neurol; 2022 Jun; 269(6):3136-3146. PubMed ID: 34820735
[TBL] [Abstract][Full Text] [Related]
18. A systematic literature review to examine the considerations around pregnancy in women of child-bearing age with myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) or aquaporin 4 neuromyelitis optica spectrum disorder (AQP4+ NMOSD).
Leite MI; Panahloo Z; Harrison N; Palace J
Mult Scler Relat Disord; 2023 Jul; 75():104760. PubMed ID: 37224631
[TBL] [Abstract][Full Text] [Related]
19. Dysphagia in neuromyelitis optica spectrum disorder and myelin oligodendrocyte glycoprotein antibody disease as a surrogate of brain involvement?
Pawlitzki M; Ahring S; Rolfes L; Dziewas R; Warnecke T; Suntrup-Krueger S; Wiendl H; Klotz L; Meuth SG; Labeit B
Eur J Neurol; 2021 May; 28(5):1765-1770. PubMed ID: 33338309
[TBL] [Abstract][Full Text] [Related]
20. Impact of COVID-19 public health measures on myelin oligodendrocyte glycoprotein IgG-associated disorders in children.
Kaseka ML; Ly M; Yea C; Longoni G; Yeh EA
Mult Scler Relat Disord; 2021 Nov; 56():103286. PubMed ID: 34627003
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
